1. Home
  2. CRSP vs AEIS Comparison

CRSP vs AEIS Comparison

Compare CRSP & AEIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • AEIS
  • Stock Information
  • Founded
  • CRSP 2013
  • AEIS 1981
  • Country
  • CRSP Switzerland
  • AEIS United States
  • Employees
  • CRSP N/A
  • AEIS N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • AEIS Industrial Machinery/Components
  • Sector
  • CRSP Health Care
  • AEIS Technology
  • Exchange
  • CRSP Nasdaq
  • AEIS Nasdaq
  • Market Cap
  • CRSP 4.3B
  • AEIS 4.3B
  • IPO Year
  • CRSP 2016
  • AEIS 1995
  • Fundamental
  • Price
  • CRSP $43.65
  • AEIS $124.13
  • Analyst Decision
  • CRSP Buy
  • AEIS Buy
  • Analyst Count
  • CRSP 18
  • AEIS 8
  • Target Price
  • CRSP $76.60
  • AEIS $117.43
  • AVG Volume (30 Days)
  • CRSP 1.8M
  • AEIS 208.8K
  • Earning Date
  • CRSP 11-05-2024
  • AEIS 02-04-2025
  • Dividend Yield
  • CRSP N/A
  • AEIS 0.33%
  • EPS Growth
  • CRSP N/A
  • AEIS N/A
  • EPS
  • CRSP N/A
  • AEIS 1.13
  • Revenue
  • CRSP $202,829,000.00
  • AEIS $1,471,910,000.00
  • Revenue This Year
  • CRSP N/A
  • AEIS N/A
  • Revenue Next Year
  • CRSP $758.18
  • AEIS $12.21
  • P/E Ratio
  • CRSP N/A
  • AEIS $105.98
  • Revenue Growth
  • CRSP 19.31
  • AEIS N/A
  • 52 Week Low
  • CRSP $42.86
  • AEIS $89.12
  • 52 Week High
  • CRSP $91.10
  • AEIS $124.02
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 39.11
  • AEIS 61.62
  • Support Level
  • CRSP $43.40
  • AEIS $116.07
  • Resistance Level
  • CRSP $53.97
  • AEIS $124.02
  • Average True Range (ATR)
  • CRSP 2.37
  • AEIS 2.70
  • MACD
  • CRSP -0.78
  • AEIS 0.26
  • Stochastic Oscillator
  • CRSP 9.53
  • AEIS 75.13

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About AEIS Advanced Energy Industries Inc.

Advanced Energy Industries Inc provides precision power-conversion measurement and control solutions that transform power into various forms for use in manufacturing and industrial equipment and applications. The firm serves original equipment manufacturers and end customers in the semiconductor, flat panel display, solar panel, and other industrial capital equipment markets. Products include thin-film power-conversion systems, which control and modify raw electrical power into a customizable, predictable power source, and power control modules, which control and measure temperature during manufacturing cycles. A majority of the firm's revenue is generated in the United States, with the rest primarily from Asia and Europe.

Share on Social Networks: